Program
※If you have registered for participation, please enter the password provided by the secretariat.
- Presidential LectureDrug discovery for myeloma from new perspectives of pathophysiology
- May 27 (Sat.) 13:30~14:00 Room 1 (5F Main Hall)
- Chairperson:
- Masahiro Abe(Kawashima Hospital)
- Speaker:
- Yutaka Hattori(Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy / Department of Hematology, Tokyo Saiseikai Central Hospital)
- Special Lecture 1Cutting edge of biology in post-genome era
- May 27 (Sat.) 15:10~16:20 Room 1 (5F Main Hall)
- Chairpersons:
- Yutaka Hattori(Keio University / Tokyo Saiseikai Central Hospital)
- Mineo Kurokawa(The University of Tokyo)
Function of extracellular vesicles in lymphoproliferative disease
- Speaker:
- Ai Kotani(Tokai University School of Medicine Advanced Medical Science)
Intracellular quality control by autophagy
- Speaker:
- Noboru Mizushima(Department of Biochemistry and Molecular Biology, Graduate School of Medicine, The University of Tokyo)
- Special Lecture 2Up-to-date of COVID-19 clinics
- May 28 (Sun.) 13:50~15:00 Room 1 (5F Main Hall)
- Chairpersons:
- Hiroshi Handa(Gunma University)
- Takahide Kikuchi(Tokyo Saiseikai Central Hospital)
Current status and future prospects of COVID-19 treatment
- Speaker:
- Norio Ohmagari(Disease Control and Prevention Center, National Center for Global Health and Medicine)
Management of patients with hematological disorders in the prolonged COVID-19 pandemic
- Speaker:
- Masao Hagihara(Department of Hematology, Eiju General Hospitlal, Japan)
- Symposium 1New developments of immunotherapy
- May 27 (Sat.) 9:00~10:15 Room 1 (5F Main Hall)
- Chairpersons:
- Yoichi Imai(Dokkyo Medical University)
- Maiko Matsushita(Keio University)
From basic and clinical studies of monoclonal antibodies for MM to the current and future status of therapy of CAR-T cell and bispecific antibodies
- Speaker:
- Yoichi Imai(Department of Hematology and Oncology, Dokkyo Medical University)
Recent Advances of Bispecific Antibody Therapy for Myeloma
- Speaker:
- Toshiki Ochi(Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine / Division of Immune Regulation, Proteo - Science Center, Ehime University)
Cancer immunotherapy to cure patients with multiple myeloma
- Speaker:
- Yuki Kagoya(Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine)
- Symposium 2“Molecular pathogenesis and treatment of high-risk myeloma”
- May 27 (Sat.) 14:10~15:00 Room 1 (5F Main Hall)
- Chairpersons:
- Akira Sakai(Fukushima Medical University)
- Yasushi Takamatsu(Fukuoka University)
Genomic risk in multiple myeloma
- Speaker:
- Hervé Avet-Loiseau(IUC-ONCOPOLE, France)
Molecular pathogenesis and treatment approach of myeloma with high-risk cytogenetics
- Speaker:
- Ichiro Hanamura(Division of Hematology, Department of Internal Medicine, Aichi Medical University, Japan)
- Symposium 3“International symposium: Progress in myeloma therapy: current status and future perspective”
- May 28 (Sun.) 9:00~10:05 Room 1 (5F Main Hall)
- Chairpersons:
- Hiroshi Kosugi(Ogaki Municipal Hospital)
- Tadao Ishida(Japanese Red Cross Medical Center)
Progress in myeloma therapy: current status and future perspective
- Speaker:
- Nikhil C. Munshi (Dana-Farber Cancer Institute, Harvard Medical School)
Progress in Myeloma Therapy: Current Status and Future Perspectives
- Speaker:
- Daryl Tan(Mount Elizabeth Novena Hospital, Singapore)
Progress in myeloma therapy: current status and future perspective in Japan
- Speaker:
- Shinsuke Iida(Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences)
- Symposium 4General management of myeloma patients
- May 28 (Sun.) 11:15~12:05 Room 1 (5F Main Hall)
- Chairpersons:
- Yasuhito Terui(Saitama Medical University Hospital)
- Masaki Ri(Nagoya City University Hospital)
Management of Multiple Myeloma Patients: From a Viewpoint of Onco-Cardiology
- Speaker:
- Hiroshi Akazawa(Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo)
Management of myeloma kidney and monoclonal gammopathy of renal significance
- Speaker:
- Shinichi Mizuno(Department of Nephrology, JCHO Sendai Hospital, Sendai, Japan)
- Plenary Session
- May 28 (Sun.) 15:10~16:15 Room 1 (5F Main Hall)
- Chairpersons:
- Masahiro Abe(Kawashima Hospital)
- Chiaki Nakaseko(International University of Health and Welfare)
The functional roles of miR-106a-5p and miR-146a-5p transferred by tumor-derived exosome in the induction of M-MDSCs in multiple myeloma
- Speaker:
- Kentaro Mizuhara(Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Japan)
The anti-myeloma efficacy of TAS0612, a triple inhibitor for RSK, AKT, and S6K
- Speaker:
- Haruya Okamoto(Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan)
Intrinsic and extrinsic regulation of BCMA expression in myeloma cells
- Speaker:
- Yusuke Inoue(Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences)
Discovery of a first-in class inhibitor for histone lysine methyltransferase MMSET, which confers cytotoxicity to t(4;14)-positive multiple myeloma
- Speaker:
- Sae Matsuoka(Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Japan)
The role of soluble SLAMF7-mediated inflammation in myeloma progression
- Speaker:
- Takeshi Harada(Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences)
- Educational Lecture 1Management for multiple myeloma based on updated guidelines
- May 27 (Sat.) 11:20~11:50 Room 1 (5F Main Hall)
- Chairperson:
- Shuji Ozaki(Tokushima Prefectural Central Hospital)
- Speaker:
- Shigeki Ito(Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Japan)
- Educational Lecture 2Pharmacokinetic aspects of drugs used for the treatment of myeloma
- May 28 (Sun.) 13:15~13:45 Room 1 (5F Main Hall)
- Chairpersons:
- Yutaka Hattori(Keio University / Tokyo Saiseikai Central Hospital)
- Hironobu Hashimoto(National Cancer Center Hospital)
- Speaker:
- Hisakazu Ohtani(Department of Clinical Pharmacy, Keio University School of Medicine)
- Oral Session
(1) NDMM Treatment-Transplant eligible/ineligible
(2) Pathophysiology & Treatment (non-clinical) 1
(3) RRMM Treatment
(4) Diagnostic Procedure (including bio-marker)
(5) Pathophysiology & Treatment (non-clinical) 2/Case Report
(6) Myeloma-related Disorders/Others
- Encore(Oral Session)1,2
- Poster Session
(1) Pathophysiology & Treatment (non-clinical)
(2) Diagnostic Procedure (including bio-marker)/Complications, Supportive Care and Comprehensive Care
(3) NDMM Treatment-Transplant eligible/RRMM Treatment
(4) Myeloma-related Disorders/Case Report 1
(5) Case Report 2/Others
- Encore(Poster Session)
- Sponsored Seminar 1How should we deal for the cancer patients complicated with COVID-19
- May 26 (Fri.) 17:00~17:50 Room 1 (5F Main Hall)
- Chairperson:
- Kazuhito Suzuki(The Jikei University)
- Speaker:
- Osamu Kobayashi(Department of Infectious Disease, National Cancer Center Hospital)
- Sponsored by GlaxoSmithKline K.K.
- Sponsored Seminar 2Positioning of CD38 monoclonal antibody (Daratumumab) for the treatment
of Multiple Myeloma and Systemic AL Amyloidosis - May 26 (Fri.) 18:00~18:50 Room 1 (5F Main Hall)
- Chairperson:
- Tadao Ishida(Japanese Red Cross Medical Center)
Multifaced benefits with daratumumab-containing treatment for untreated transplant-ineligible multiple myeloma
- Speaker:
- Junya Kuroda(Division of Hematology and Oncology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan)
Treatment strategy of AL amyloidosis
- Speaker:
- Shin-ichi Fuchida(Department of Hematology, JCHO Kyoto Kuramaguchi Medical Center)
- Sponsored by Janssen Pharmaceutical K.K.
- Sponsored Seminar 3About the well-being of patients with multiple myeloma
- May 27 (Sat.) 10:25~11:15 Room 1 (5F Main Hall)
- Chairperson:
- Yotaro Tamai(Shonan Kamakura General Hospital)
Experience with Safe Use of Carfilzomib through Risk Assessment, Early Detection, and Intervention of Cardiac-Related Adverse Events
- Speaker:
- Yusuke Koba(Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center)
Making the best use of carfilzomib for the well-being of multiple myeloma patients
- Speaker:
- Morio Matsumoto(National Hospital Organization, Shibukawa Medical Center)
- Sponsored by ONO PHARMACEUTICAL CO., LTD.
- Sponsored Seminar 4Chromosomal abnormalities in multiple myeloma:
which ones to assess? With which technique? - May 27 (Sat.) 10:25~11:15 Room 2 (5F Large Hall)
- Chairperson:
- Naoki Hosen(Osaka University)
- Speaker:
- Hervé Avet-Loiseau(IUC-ONCOPOLE, France)
- Sponsored by AbbVie GK
- Sponsored Seminar 5Current status and issues of CAR-T cell therapy for multiple myeloma in a
routine practice - May 27 (Sat.) 16:30~17:20 Room 1 (5F Main Hall)
- Chairperson:
- Junya Kuroda(Kyoto Prefectural University of Medicine)
- Speaker:
- Masaki Ri(Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Japan / Division of Blood Transfusion and Cell Therapy, Nagoya City University Hospital, Japan)
- Sponsored by Bristol-Myers Squibb K.K.
- Sponsored Seminar 6CAR T-cell therapy for multiple myeloma
- May 28 (Sun.) 10:15~11:05 Room 1 (5F Main Hall)
- Chairperson:
- Masahiro Abe(Kawashima Hospital / Tokushima University)
- Speaker:
- Satoshi Yoshihara(Department of Respiratory Medicine and Hematology, Hyogo Medical University, Japan)
- Sponsored by Janssen Pharmaceutical K.K.
- Sponsored Seminar 7Clinical Trial Evidence to Real-World Evidence
- May 28 (Sun.) 10:15~11:05 Room 2 (5F Large Hall)
- Chairperson:
- Hirohiko Shibayama(National Hospital Organization, Osaka National Hospital)
- Speaker:
- Teruhito Takakuwa(Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University)
- Sponsored by Takeda Pharmaceutical Company Limited
- Morning Seminar 1Treatment strategies for Lymphoplasmacytic Lymphoma/ Waldenström's Macroglobulinemia -including our experiences treating Bing–Neel syndrome-
- May 28 (Sun.) 8:00~8:40 Room 1 (5F Main Hall)
- Chairperson:
- Naohiro Sekiguchi(National Hospital Organization, Disaster Medical Center)
- Speaker:
- Masuho Saburi(Department of Hematology, Oita Prefectural Hospital, Japan)
- Sponsored by ONO PHARMACEUTICAL CO., LTD.
- Morning Seminar 2Response evaluation on patients undergoing anti-CD38 therapy, Daratumumab and Isatuximab, should be determined by the HYDRASHIFT assays
- May 28 (Sun.) 8:00~8:40 Room 2 (5F Large Hall)
- Chairperson:
- Hiroyuki Takamatsu(Kanazawa University)
- Speaker:
- Kazunori Miyake(Department of Clinical Laboratory, Cancer Institute Hospital of Japanese Foundation for Cancer Research / Faculty of Medical Science, Juntendo University)
- Sponsored by SEBIA JAPAN K.K.
- Luncheon Seminar 1The significance of the combination therapy of daratumumab and IMiDs for
multiple myeloma from scientific and clinical aspects - May 27 (Sat.) 12:00~12:50 Room 1 (5F Main Hall)
- Chairperson:
- Chiaki Nakaseko(International University of Health and Welfare)
Reshaping a treatment paradigm in multiple myeloma with the development of immunotherapeutic modalities
- Speaker:
- Takeshi Harada(Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences)
Real-world experience of DRd regimen for transplant-ineligible newly diagnosed multiple myeloma
- Speaker:
- Yuichi Horigome(Department of Hematology, Kitasato University Graduate School of Medical Sciences, Japan)
- Sponsored by Janssen Pharmaceutical K.K.
- Luncheon Seminar 2The positioning of PI continuation therapy in MM treatment sequence
- May 27 (Sat.) 12:00~12:50 Room 2 (5F Large Hall)
- Chairperson:
- Hirokazu Murakami(Gunma University of Health and Welfare)
Treatment strategy of MM considering the treatment sequence
-The significance of maintenance therapy -
- Speaker:
- Kenshi Suzuki(Department of Hematology, Japanese Red Cross Medical Center)
Multiple myeloma treatment strategy considering the treatment sequence
-Updates on PI continuous therapy in RRMM-
- Speaker:
- Naoki Takezako(Nerima-Hikarigaoka Hospital Department of Hematology)
- Sponsored by Takeda Pharmaceutical Company Limited
- Luncheon Seminar 3Two years have passed since the Sarclisa® have launched-Considering
the position of Sarclisa from the basic and clinical perspectives - May 28 (Sun.) 12:15~13:05 Room 1 (5F Main Hall)
- Chairperson:
- Shuji Ozaki(Tokushima Prefectural Central Hospital)
- Speakers:
- Yusuke Furukawa(Center for Medical Education, Teikyo University of Science / Center for Molecular Medicine, Jichi Medical University)
- Takashi Ikeda(Shizuoka Cancer Center)
- Sponsored by Sanofi K.K.
- Luncheon Seminar 4Treatment Sequence considering Tumor and the Immune Microenvironment
- May 28 (Sun.) 12:15~13:05 Room 2 (5F Large Hall)
- Chairperson:
- Kazutaka Sunami(NHO Okayama Medical Center)
The clinical application of myeloma microenvironment evaluation
- Speaker:
- Michiko Ichii(Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan)
Multiple myeloma treatment sequence in the immune-based therapy era, including timing of pomalidomide-intensified antibody treatment
- Speaker:
- Hideto Tamura(Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Japan)
- Sponsored by Bristol-Myers Squibb K.K.